{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:25:35Z","timestamp":1784913935049,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00134","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T11:46:39Z","timestamp":1519386399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats"],"prefix":"10.3389","volume":"9","author":[{"given":"Jingwen","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulinuer","family":"Wumaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"B1","unstructured":"Discovery Studio 3.1. 3.12011"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth","volume":"92","author":"Ameshima","year":"2003","journal-title":"Circ. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1016\/j.bbagen.2013.06.021","article-title":"Honokiol: a non-adipogenic PPARgamma agonist from nature","volume":"1830","author":"Atanasov","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/1060028017697424","article-title":"Selexipag, an oral prostacyclin-receptor agonist for pulmonary arterial hypertension","volume":"51","author":"Baker","year":"2017","journal-title":"Annu. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17476348.2017.1317599","article-title":"The prostacyclin pathway in pulmonary arterial hypertension: a clinical review","volume":"11","author":"Del Pozo","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbrc.2007.06.135","article-title":"IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues","volume":"360","author":"Falcetti","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2174\/092986709788186165","article-title":"Structural insight into PPARgamma ligands binding","volume":"16","author":"Farce","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Galie","year":"2016","journal-title":"Rev. Esp. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1097-2765(00)80448-7","article-title":"Asymmetry in the PPARgamma\/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors","volume":"5","author":"Gampe","year":"2000","journal-title":"Mol. Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur. Respir. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/2045-8932.78101","article-title":"Is peroxisome proliferator-activated receptor gamma (PPARgamma) a therapeutic target for the treatment of pulmonary hypertension?","volume":"1","author":"Green","year":"2011","journal-title":"Pulm. Circ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1574-1400(09)00502-7","article-title":"Quantifying uncertainty and sampling quality in biomolecular simulations","volume":"5","author":"Grossfield","year":"2009","journal-title":"Annu. Rep. Comput. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1067\/mtc.2003.107","article-title":"Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery","volume":"125","author":"Hach\u00e9","year":"2003","journal-title":"J. Thoracic Cardiovasc. Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17512433.2017.1322900","article-title":"Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review","volume":"10","author":"Honorato P\u00e9rez","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"B19","first-page":"705","article-title":"[Fundamental and clinical studies on cefminox in the field of pediatrics]","volume":"38","author":"Iwai","year":"1985","journal-title":"Jpn. J. Antibiot."},{"key":"B20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1089\/scd.2010.0591","article-title":"Peroxisome proliferator-activated receptor gamma\/signal transducers and activators of transcription 5A pathway plays a key factor in adipogenesis of human bone marrow-derived stromal cells and 3T3-L1 preadipocytes","volume":"21","author":"Jung","year":"2012","journal-title":"Stem Cells Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1210\/en.2011-1725","article-title":"The ubiquitin ligase Siah2 regulates PPARgamma activity in adipocytes","volume":"153","author":"Kilroy","year":"2012","journal-title":"Endocrinology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"816856","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR gamma partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Rese."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"B24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.200710-1519OC","article-title":"Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension","volume":"178","author":"Lai","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.lungcan.2005.10.010","article-title":"PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression","volume":"51","author":"Lee","year":"2006","journal-title":"Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1532\/IJH97.A30615","article-title":"Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells","volume":"85","author":"Lee","year":"2007","journal-title":"Int. J. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/0003-4819-139-4-200308190-00025","article-title":"Treatment of severe pulmonary hypertension with inhaled iloprost","volume":"139","author":"Leuchte","year":"2003","journal-title":"Ann. Intern. Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/TCRM.S75122","article-title":"Prostanoid therapies in the management of pulmonary arterial hypertension","volume":"11","author":"LeVarge","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.18632\/oncotarget.6826","article-title":"TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","first-page":"374075","DOI":"10.1155\/2014\/374075","article-title":"Rosiglitazone attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors","volume":"2014","author":"Liu","year":"2014","journal-title":"PPAR Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e56774","DOI":"10.1371\/journal.pone.0056774","article-title":"Tanshinone IIA inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt\/Skp2\/p27-associated pathway","volume":"8","author":"Luo","year":"2013","journal-title":"PLoS ONE"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7768","DOI":"10.1021\/jm800733h","article-title":"Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design","volume":"51","author":"Montanari","year":"2008","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1165\/rcmb.2008-0132OC","article-title":"Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model","volume":"42","author":"Nisbet","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40264-015-0365-x","article-title":"Comparative safety and tolerability of prostacyclins in pulmonary hypertension","volume":"39","author":"O'Connell","year":"2016","journal-title":"Drug Saf."},{"key":"B35","first-page":"1165","article-title":"[Clinical study of cefminox in respiratory tract infections]","volume":"38","author":"Odagiri","year":"1985","journal-title":"Jpn. J. Antibiot."},{"key":"B36","doi-asserted-by":"publisher","first-page":"8725","DOI":"10.1093\/nar\/gkv872","article-title":"ATP dependent NS3 helicase interaction with RNA: insights from molecular simulations","volume":"43","author":"P\u00e9rez-Villa","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/978-1-60761-500-2_29","article-title":"PPARgamma and the pathobiology of pulmonary arterial hypertension","volume":"661","author":"Rabinovitch","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/VHRM.S50368","article-title":"Epoprostenol sodium for treatment of pulmonary arterial hypertension","volume":"11","author":"Saito","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1074\/jbc.M207420200","article-title":"The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling","volume":"278","author":"Stitham","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1753465809369619","article-title":"PPARgamma as a potential therapeutic target in pulmonary hypertension","volume":"4","author":"Sutliff","year":"2010","journal-title":"Ther. Adv. Respir. Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7761","DOI":"10.1021\/bi0155091","article-title":"Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs)","volume":"40","author":"Teller","year":"2001","journal-title":"Biochemistry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1078-5884(03)00385-X","article-title":"Prostacyclin: a vascular mediator","volume":"26","author":"Vane","year":"2003","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/00325481.2016.1188664","article-title":"Update on pulmonary arterial hypertension pharmacotherapy","volume":"128","author":"Velayati","year":"2016","journal-title":"Postgrad. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER\u2014A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/br.2015.465","article-title":"Activation of peroxisome proliferator-activated receptor gamma ameliorates monocrotaline-induced pulmonary arterial hypertension in rats","volume":"3","author":"Xie","year":"2015","journal-title":"Biomed. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"45687","DOI":"10.18632\/oncotarget.9920","article-title":"miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jmgm.2016.02.006","article-title":"Novel binding patterns between ganoderic acids and neuraminidase: insights from docking, molecular dynamics and MM\/PBSA studies","volume":"65","author":"Yang","year":"2016","journal-title":"J. Mol. Graph. Model."},{"key":"B49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10822-013-9691-1","article-title":"Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study","volume":"27","author":"Yang","year":"2013","journal-title":"J. Comput. Aided Mol. Des."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T11:46:39Z","timestamp":1519386399000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":49,"alternative-id":["10.3389\/fphar.2018.00134"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00134","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"article-number":"134"}}